Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant

Mucosal Immunology

Volumn 3, Issue 4, 2010, Pages 374-386

  Sjoblom Hallen A ^a   Marklund, U ^a   Nerstedt, A ^b   Schon K ^a   Ekman, L ^a   Bergqvist, P ^a   Lowenadler B ^c   Lycke, N Y ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; STAT PROTEIN; STAT3 ALPHA PROTEIN; STAT3 BETA PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEYER PATCH; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

EID: 77953769152     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2010.16     Document Type: Article

References (50)

1. Lycke, N. Mechanisms of adjuvant action. In Vaccine Adjuvants and Delivery Systems (Singh, M., ed) 53-79 (John Wiley & Sons, Hoboken, NJ, 2007).
2. Levine, M. M. & Sztein, M. B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat. Immunol. 5, 460-464 (2004).
3. Shaffer, A. L. et al. Signatures of the immune response. Immunity 15, 375-385 (2001).
4. Ricciardi-Castagnoli, P. & Granucci, F. Opinion: interpretation of the complexity of innate immune responses by functional genomics. Nat. Rev. Immunol. 2, 881-889 (2002).
5. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11, S45-S53 (2005).
6. Rappuoli, R., Pizza, M., Douce, G. & Dougan, G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 20, 493-500 (1999).
7. Fujihashi, K., Koga, T., van Ginkel, F. W., Hagiwara, Y. & McGhee, J. R. A dilemma for mucosal vaccination: effi cacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20, 2431-2438 (2002).
8. Torgersen, K. M., Aandahl, E. M. & Tasken, K. Molecular architecture of signal complexes regulating immune cell function. Handb. Exp. Pharmacol. 4, 327-363 (2008).
9. Elson, C. O. & Dertzbaugh, M. T. Mucosal adjuvants. In Mucosal Immunology, Vol 1 (Mestecky, J., et al. eds) 967-986 (Elsevier Academic Press, San Diego, CA, 2005).
10. Lycke, N., Severinson, E. & Strober, W. Cholera toxin acts synergistically with IL-4 to promote IgG1 switch differentiation. J. Immunol. 145, 3316-3324 (1990).
11. Grdic, D. et al. Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin. J. Immunol. 175, 5192-5202 (2005).
12. Cong, Y., Oliver, A. O. & Elson, C. O. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur. J. Immunol. 31, 64-71 (2001).
13. Lavelle, E. C. et al. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J. Leukoc. Biol. 75, 756-763 (2004).
14. Gagliardi, M. C. & De Magistris, M. T. Maturation of human dendritic cells induced by the adjuvant cholera toxin: role of cAMP on chemokine receptor expression. Vaccine 21, 856-861 (2003).
15. Braun, M. C., He, J., Wu, C. Y. & Kelsall, B. L. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J. Exp. Med. 189, 541-552 (1999).
16. Brierley, M. M. & Fish, E. N. Stats: multifaceted regulators of transcription. J. Interferon Cytokine Res. 25, 733-744 (2005).
17. Fu, X. Y. STAT3 in immune responses and infl ammatory bowel diseases. Cell Res. 16, 214-219 (2006).
18. Sakamori, R. et al. Signal transducer and activator of transcription 3 signaling within hepatocytes attenuates systemic infl ammatory response and lethality in septic mice. Hepatology 46, 1564-1573 (2007).
19. Liu, X., Lee, Y. S., Yu, C. R. & Egwuagu, C. E. Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J. Immunol. 180, 6070-6076 (2008).
20. Ding, B. B. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515-1523 (2008).
21. Fornek, J. L. et al. Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 107, 1085-1091 (2006).
22. Granucci, F. et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2, 882-888 (2001).
23. Tureci, O. et al. Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. Faseb. J. 17, 836-847 (2003).
24. Royaee, A. R. et al. Cholera toxin induced novel genes in human lymphocytes and monocytes. Mol. Immunol. 43, 1267-1274 (2006).
25. Hirano, T., Ishihara, K. & Hibi, M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548-2556 (2000).
26. Nishinakamura, H. et al. An RNA-binding protein alphaCP-1 is involved in the STAT3-mediated suppression of NF-kappaB transcriptional activity. Int. Immunol. 19, 609-619 (2007).
27. Royaee, A. R. et al. Induction of immunomodulator transcriptional responses by cholera toxin. Mol. Immunol. 43, 1020-1028 (2006).
28. Tritto, E. et al. The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J. Immunol. 179, 5346-5357 (2007).
29. Royaee, A. R., Mendis, C., Das, R., Jett, M. & Yang, D. C. Cholera toxin induced gene expression alterations. Mol. Immunol. 43, 702-709 (2006).
30. Burkart, V. et al. Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinfl ammatory responsiveness to lipopolysaccharide. J. Immunol. 168, 1730-1737 (2002).
31. Calame, K. Activation-dependent induction of Blimp-1. Curr. Opin. Immunol. 20, 259-264 (2008).
32. Murray, P. J. Understanding and exploiting the endogenous interleukin-10/ STAT3-mediated anti-infl ammatory response. Curr. Opin. Pharmacol. 6, 379-386 (2006).
33. Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49 (1999).
34. Williams, L., Bradley, L., Smith, A. & Foxwell, B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-infl ammatory effects of IL-10 in human macrophages. J. Immunol. 172, 567-576 (2004).
35. Owaki, T. et al. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinfl ammatory cytokine production. J. Immunol. 180, 2903-2911 (2008).
36. Matsumura, Y. et al. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-defi cient dendritic cells. J. Immunol. 179, 2170-2179 (2007).
37. Mathur, A. N. et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 178, 4901-4907 (2007).
38. Eddahri, F. et al. Interleukin-6/STAT3 signalling regulates the ability of naive T cells to acquire B cell help capacities. Blood 113, 2426-2433 (2009).
39. Holmgren, J. Actions of cholera toxin and the prevention and treatment of cholera. Nature 292, 413-417 (1981).
40. Liu, A. M. et al. Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase. J. Biol. Chem. 281, 35812-35825 (2006).
41. Maritano, D. et al. The STAT3 isoforms alpha and beta have unique and specifi c functions. Nat. Immunol. 5, 401-409 (2004).
42. Dewilde, S., Vercelli, A., Chiarle, R. & Poli, V. Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. Front Biosci. 13, 6501-6514 (2008).
43. Levy, D. E. & Lee, C. K. What does Stat3 do? J. Clin. Invest. 109, 1143-1148 (2002).
44. Blumberg, R. S., Pitman, R. S., Taylor, C. T. & Colgan, S. P. Cholera toxin potentiates infl uences of IFN-gamma through activation of NF-kappaB and release of tumor necrosis factor-alpha. J. Interferon Cytokine Res. 25, 209-219 (2005).
45. Kim, K. J., Kanellopoulos-Langevin, C., Merwin, R. M., Sachs, D. H. & Asofsky, R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122, 549-554 (1979).
46. Kim, K. J., Chaouat, G., Leiserson, W. M., King, J. & De Maeyer, E. Characterization of T-cell-soluble factors modulating the expression of Ia and H-2 antigens on BALB/c B lymphoma cell lines. Cell Immunol. 76, 253-267 (1983).
47. Lycke, N. A molecular approach to the construction of an effective mucosal vaccine adjuvant: studies based on cholera toxin ADP-ribosylation and cell targeting. In Essentials of Mucosal Immunology (Kagnoff, M. & Kiyono, H., eds) 563-580 (Academic Press Inc, San Diego, 1996).
48. Akhiani, A. A., Stensson, A., Schon, K. & Lycke, N. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand. J. Immunol. 63, 97-105 (2006).
49. Lycke, N. Y. Cholera toxin promotes B cell isotype switching by two different mechanisms. cAMP induction augments germ-line Ig H-chain RNA transcripts whereas membrane ganglioside GM1-receptor binding enhances later events in differentiation. J. Immunol. 150, 4810-4821 (1993).
50. Marklund, U., Lightfoot, K. & Cantrell, D. Intracellular location and cell contextdependent function of protein kinase D. Immunity 19, 491-501 (2003).